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morbidity andmortality, relapse has not altered signiﬁcantly.
We performed a single institution review of relapse
following allo-HSCT in patients with AL examining salvage
therapy and characteristics of long term survivors.
Methods: All adult patients who proceeded to an allo-HSCT
for AL from 1998-2012 (n¼100) were reviewed. 24 relapsed
following allo-HSCT and a detailed review of salvage treat-
ments and outcomes was made. Probability of overall sur-
vival (POS) and 95% conﬁdence interval (CI) were calculated
by actuarial method.
Results: The 5 year POS of the 100 patients with AL pro-
ceeding to allo-HSCT was 71 % (CI 61-80%). Of 24 relapsing
after allo-HSCT, 17 had initial diagnosis AML, and 7 ALL. The
AML groupmedian agewas 49y (range 22-65), 53%male. Ten
patients received sibling donors, 6 unrelated donors and 1
patient a related haplo-identical donor. Relapses were
mostly systemic (14) and extra medullary (EM) 3 of the 17
cases. Median time to relapse was 13 months (3-57). Salvage
treatments were: second allo-HSCT +/- chemotherapy
(chemo) (n¼5); donor lymphocyte infusion (DLI) +/- chemo
(n¼5); chemo +/- withdrawal of immunosuppression (WI)
(n¼4); or palliative/supportive care (n¼3). Ten patients (57%)
achieved complete response (CR), and CR was maintained by
8 patients (47%), with a median follow up 34 months (range
8-66). All deaths (n¼9) were due to disease. All 3 patients
with EM relapse are in ongoing remission.
In the ALL group (n¼7) median age was 22y (range 19-
52), 57% of male. 3 were sibling donor transplants, 3 unre-
lated and 1 patient received a double cord. Relapse was
systemic in 5 patients, and EM in 2. Median time to relapse
was 13 months (range 3-57). Salvage treatments comprised:
chemo +/- WI (n¼3), second allo-HSCT +/- salvage chemo
(n¼2), DLI +/- salvage chemo (n¼1), with 1 patient receiving
novel monoclonal antibody therapy. Three patients achieved
a CR, however, all died, 2 of disease progression. Two patients
remain alive in PR with ongoing salvage treatment to be
determined.
Conclusions: Despite advances in allo-HSCT, long term sur-
vival outcomes for patients with ALL who relapse after allo-
HSCT remain poor. However, in contrast, for patients with
AML who relapse, durable long-term remissions can be
achieved with salvage therapy (with and without second
allo-HSCT) with almost half of our patients (47%) in ongoing
CR at a median of 34 months (range 8-66). As shown in other
studies EM relapse, may be salvaged with good long term
results.331
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Background: Over the last decade, unrelated donors have
become a vital resource for hematopoietic stem cell trans-
plantation (HSCT) and the number of allogeneic HSCT (allo-
HSCT) has increased signiﬁcantly. While invasive fungal
infections (IFIs) remain major concerns in these patients,
data regarding impact of these infections on mortality,length of hospital stay, and hospital charge are limited in the
United States at a national level. Additionally, with many
updates in transplant practice, risk factors for IFIs in these
patients may have changed.
Methods: To assess risk factors and impact of IFIs on
mortality, length of hospital stay, and hospital charges, a
quantitative and cross-sectional design was used to analyze
secondary data from the 2010 Healthcare Cost and Utiliza-
tion Project - Nationwide Inpatient Sample (HCUP NIS)
database. Chi-square test, Mann-Whitney test, and multiple
logistic regression were used for statistical analyses.
Results: A total of 5,753 weighted hospital records of allo-
HSCT were identiﬁed with a mean age of 44.8  19.1 years.
The IFI rate was 7.8% (451), with aspergillosis (30.6%) and
candidiasis (9.6%) as the two most common IFIs. Compared
to patients without IFIs, patients with IFIs had nearly 5 times
higher mortality (25.1% vs. 5.1%), longer hospital stays, and
higher hospital charges (p < .01). Multiple regression ana-
lyses on risk factors conﬁrmed presence of graft-versus-host
disease as a recognized risk factor for IFIs. However, younger
age, female gender, and related donors were also identiﬁed
as risk factors for IFIs in this analysis. The underlying reasons
for these unexpected ﬁndings will be explored.
Conclusions: An analysis of a large U.S. inpatient database
conﬁrmed that allo-HSCT patients with IFIs have higher
mortality and higher health care costs. The risk factors for
IFIs have been identiﬁed that could enable better manage-
ment and control of these infections.332
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Background: ABO typing is not readily available within
donor databases. ABO incompatibility between donor and
recipient is not considered a hurdle to an allogeneic he-
matopoietic stem cell transplantation (ALLOSCT). Conﬂicting
data still exist as to its inﬂuence on graft-versus-host disease
(GVHD), relapse, and survival.
Method: We retrospectively examined the impact of ABO
compatibility on outcomes of 109 patients who underwent
matched unrelated donor (MUD), matched related (REL) and
cord blood (CBU) ALLOSCT at our institution since 01/01/
2010.
Results: Median age was 58 years (range, 19.9- 83.6); 33
(30%) were female; 64 (59%) patients had a myeloid, 34 (31%)
lymhoid, 8 (7%) plasma cell and 3 (3%) had other disorder; 57
(52%) patients received myeloablative, 25 (23%) non-
myeloablative and 27 (25%) received reduced intensity con-
ditioning. The stem cell sources were represented by 78
(72%) MUDs,15 (14%) RELs and 16 (15%) CBUs. 80 (86%) of the
MUD and REL transplants were 10/10, 11 (13%) were 9/10, 1
